BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Z, Shen W, Li X, Feng Y, Qian K, Wang G, Gao Y, Xu X, Zhang S, Yue L, Cao J. The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells. Drug Des Devel Ther 2020;14:3099-110. [PMID: 32801648 DOI: 10.2147/DDDT.S242557] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou T, Liu J, Xie Y, Yuan S, Guo Y, Bai W, Zhao K, Jiang W, Wang H, Wang H, Zhao T, Huang C, Gao S, Wang X, Yang S, Hao J. ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4. Gut 2022;71:357-71. [PMID: 33674341 DOI: 10.1136/gutjnl-2020-321952] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Pan Y, Li J, Lou S, Chen W, Lin Y, Shen N, Li Y. Down-Regulated miR-130a/b Attenuates Rhabdomyosarcoma Proliferation via PPARG. Front Mol Biosci 2022;8:766887. [DOI: 10.3389/fmolb.2021.766887] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yang S, Han G, Chen Q, Yu L, Wang P, Zhang Q, Dong J, Zhang W, Huang J. Au-Pt Nanoparticle Formulation as a Radiosensitizer for Radiotherapy with Dual Effects. Int J Nanomedicine 2021;16:239-48. [PMID: 33469284 DOI: 10.2147/IJN.S287523] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]